The use of genomic assays reduces rates of chemotherapy: a single-institution experience

ConclusionWithin our institution, overall rates of chemotherapy have reduced since the introduction of Oncotype DX with the results more marked in subgroups of traditional indicators of tumour aggression. As genomic assays provide a more accurate prediction of the benefit of chemotherapy, its overall reduction has potential cost saving implications as well as reducing risk in patients who will derive little benefit.
Source: Irish Journal of Medical Science - Category: General Medicine Source Type: research